Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fondazione del Piemonte per l'Oncologia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Kaiser Permanente
National Institutes of Health Clinical Center (CC)
University of Pennsylvania
Duke University
Washington University School of Medicine
Ulsan University Hospital
University of Colorado, Denver
Unity Health Toronto
City of Hope Medical Center
University of Nebraska
EXoPERT
Colorado State University
Orano Med LLC
Eli Lilly and Company
Novartis
Pfizer
Var2 Pharmaceuticals
Universidad Complutense de Madrid
Dokuz Eylul University
University of Salamanca
Centre Hospitalier Universitaire de Besancon
AC Camargo Cancer Center
City of Hope Medical Center
Centre Hospitalier Universitaire de Nīmes
NantCell, Inc.
Vejle Hospital
City of Hope Medical Center
AstraZeneca
Memorial Sloan Kettering Cancer Center
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Virginia Commonwealth University
University of Calgary
IRCCS San Raffaele
New Mexico Cancer Research Alliance
Washington University School of Medicine
Travera Inc
Arab American University (Palestine)
A2 Biotherapeutics Inc.
Centre Hospitalier de Valence
University of Florida
Eli Lilly and Company